{
    "key_points": [
        "FDA expands Pfizer-BioNTech COVID-19 booster eligibility to 16- and 17-year-olds.",
        "Single booster dose authorized at least six months after primary Pfizer-BioNTech vaccination.",
        "Acting FDA Commissioner Janet Woodcock, M.D., stresses continued importance of vaccinations and boosters.",
        "Present action follows Nov. 19 authorization for booster doses for individuals 18 and older.",
        "Only Pfizer-BioNTech COVID-19 Vaccine and Comirnaty authorized for the 16- and 17-year-old age group.",
        "Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research, cites waning vaccine effectiveness as rationale for boosters.",
        "FDA's analysis of immune response supports booster dose effectiveness in youth and adults.",
        "FDA assesses benefits of booster dose outweigh risks of myocarditis and pericarditis in younger age group.",
        "Pfizer conducting studies on myocarditis and pericarditis risks; FDA and CDC monitor safety.",
        "FDA did not convene Vaccines and Related Biological Products Advisory Committee for the decision."
    ],
    "spokespersons": [
        "Janet Woodcock, M.D. (Acting FDA Commissioner)",
        "Peter Marks, M.D., Ph.D. (Director of the FDA’s Center for Biologics Evaluation and Research)"
    ],
    "article_type": "government agency statement",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}